Warburg Pincus related stories
All articles and analysis
Warburg Pincus Buys JHP PharmaceuticalsWarburg Pincus has acquired JHP Pharmaceuticals for $195 million. The seller is Morgan Stanley Principal Investments. JHP's current management team will continue to hold an interest. Parsippany, N.J.-based JHP specializes in sterile injectable products. Morgan Stanley & Co. advised JHP.
- Consolidated Precision Products Buys Turbine Technologies
Consolidated Precision Products Corp., which is owned by Warburg Pincus, has acquired Turbine Technologies Group from ESCO Corp. Terms of the transaction were not disclosed. Warburg Pincus bought Consolidated Precision in October 2011.
- Korean prosecutors indict Warburg Pincus exec
Prosecutors in Seoul have indicted the head of Warburg Pincus in Korea on charges of insider trading in LG Card, an investment from which the private equity firm exited in 2003.
- Warburg Pincus-led group invests in new annuities business
New York-based private equity firm Warburg Pincus, JP Morgan and the Royal Bank of Scotland have put an undisclosed amount into a new business focusing on UK annuities.
- Lightyear sells Telmar to Warburg Pincus
The New York-based firm will exit the communications company for an undisclosed amount.
- Morgan Stanley acquires 75% stake in Ssangyong
Morgan Stanley Private Equity Asia is pushing ahead with an investment in Korea at a time when a number of heavyweight US GPs are under scrutiny from the Korean authorities.
- US VC stays strong despite few IPOs
New data from the National Venture Capital Association shows that long-term performance in the US remains strong despite dismal IPO valuation. Dave Keating reports.
- SEP launches Fund III with £120m
The Scottish investor has raised £120m for its third venture capital fund, although no final target size has yet been decided.
- Warburg cashes out of Czech pharma business
The global investor has generated around $1.2bn in total from its investment in pharmaceutical group Zentiva, which it acquired in 1998.
- Report: Harbin syndication falters
The syndication of a $282m leveraged loan connected to a private equity investment in China’s Harbin Pharmaceutical appears to be struggling to attract support.